0,1,2,3,4,5,6,7,8
Table 11 continued,,,,,,,,
Bispeciﬁc,Subgroup,Group,Light chain,Number of clinical,Immune cell,Most,Company or,Reference for platform
antibody,,in,solution,candidate,redirected,advanced,institute,
platform,,Fig. 3,,antibodies,candidates,candidate,,
BiTE,Antibody,D,NA,5,5,Approved,Amgen,"Mack et al., 1995; Schlereth"
,fragment-,,,,,in US,(Micromet,"et al., 2005; Baeuerle et al.,"
,based,,,,,and EU,acquisition),2008
TandAb,Antibody,D,NA,2,2,Phase 2,Afﬁmed,"Kipriyanov et al., 1999"
,fragment-,,,,,,,
,based,,,,,,,
Tandem,Antibody,D,NA,4,0,Phase 2,EngeneIC and,"Madrenas et al., 2004"
scFv,fragment-,,,,,,several others,
,based,,,,,,,
Dock-and-,Antibody,D,NA,1,0,Phase 2,Immunomedics,"Sharkey et al., 2010"
Lock,fragment-,,,,,,,
,based,,,,,,,
DART and,Antibody,D,NA,6,5,Phase 1,Macrogenics,"Johnson et al., 2010; Root"
DART-Fc,fragment-,,,,,,,"et al., 2016"
,based,,,,,,,
Nanobody-,Antibody,D,NA,2,0,Phase 1,Ablynx,"Van Heusden et al., 2013"
based,fragment-,,,,,,,
,based,,,,,,,
TCR-scFv,Antibody,D,NA,1,1,Phase 1,Immunocore,"Bossi et al., 2014"
,fragment-,,,,,,,
,based,,,,,,,
ADAPTIRTM,Antibody,D,NA,1,1,Phase 1,Aptevo,"Hernandez-Hoyos et al., 2016"
,fragment-,,,,,,,
,based,,,,,,,
Unknown,IgG-based,-,unk,1,0,Phase 1,BioCad,(NCT03103451)
design,,,,,,,,
Totals,24 different,,–,61 different,27,–,–,–
,known,,,candidates,,,,
,platforms,,,,,,,
